semaglutide 2.5mg Obesity The FDA has approved a

GLP-1 Synthesis GLP-1 and GLP-2 were identified in the distal small intestinal mucosa as the product of post-translational processing by prohormone convertase 1/3 (PC1/3) of the proglucagon gene product (9) which in the Islets is processed by PC2 to yield glucagon (75, 87, 97)

About The Christopher Group Through its award-winning, customized HR solutions, The Christopher Group (TCG) delivers critical human capital solutions in the area of executive HR search, interim HR leaders, fractional CHROs, and HR advisory and consulting

Timers that nudge you to take short breaks can help you reframe decisions, and spend monitors add transparency to your session history

Hanmi, Sanfer Partner to Bring GLP-1 Therapy to Mexico Hanmi Pharmaceutical has signed an exclusive distribution agreement with Mexico-based Laboratorios Sanfer to introduce efpeglenatide, a GLP-1 therapy for obesity, alongside Hanmis Dapalon Family diabetes treatments, marking a step in the South Korean companys global expansion strategy focused on metabolic diseases